{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-000379","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.936348+00:00","generated_at":"2026-06-07T02:05:57.594980+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Precigen announces PRGN-2012 Phase 2 data expected Q2 2024; BLA submission planned H2 2024","bullets":["PRGN-2012 Phase 2 pivotal data in RRP anticipated Q2 2024; BLA submission under accelerated approval H2 2024.","Commercial readiness preparations underway for potential PRGN-2012 launch in 2025.","PRGN-2009 Phase 2 study in OPSCC enrolling; cervical cancer trial to start Q1 2024.","PRGN-3006 Phase 1b dose expansion interim data expected H2 2024; Phase 1 showed 27% ORR in r/r AML.","New CD19 UltraCAR-T preclinical data presented; Phase 1 study preparation underway."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-000379","json":"https://secwatch.observer/filing/0000950103-24-000379.json","markdown":"https://secwatch.observer/filing/0000950103-24-000379.md","text":"https://secwatch.observer/filing/0000950103-24-000379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324000379/0000950103-24-000379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324000379/dp205018_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:05:57.594980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}